European Primary Care Cardiovascular Society

High CV risk in obese women even in the absence of metabolic abnormalities

June 13, 2018 - Eckel N, et al. - Lancet Diab Endocrin 2018

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

What’s the evidence that diabetes is linked to CVD and an update on managing CV risk in diabetes

EPCCS CV Summit 2018

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Xavier Cos, Barcelona, Spain
A recording of the lecture by Prof. Cos on the evidence fro diabetes and accelerated vascular disease, and which interventions can change this relationship.

EPCCS 2018 A recording of the lecture by Prof. Cos on the evidence fro diabetes and accelerated vascular disease, and which interventions can change this relationship.

Superior improvement of HbA1c with GLP-1 receptor agonist compared to SGLT2 inhibitor

May 30, 2018 - news

Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.

All-cause and CV mortality reduced by beta-blockers in non-diabetic and diabetic HF patients

May 29, 2018 - news
A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.

ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.

BMI trajectories from child to adult affect CV risk factors in mid-adulthood

May 7, 2018 - Buscot M-J, et al. - Eur Heart J 2018

Obesity in childhood that persists or worsens during adulthood is associated with higher risks of developing hypertension, T2DM, and dyslipidemia.

Management of CV risk that comes with T2DM in light of novel treatment options

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs
In his presentation, prof. Cos considered recent observations that novel classes of antidiabetic drugs can provide CV benefit in T2DM patients. Cos, Brotons and Hobbs discuss how this can improve management and outcomes of these patients.

In his presentation, prof. Cos considered recent observations that novel classes of antidiabetic drugs can provide CV benefit in T2DM patients. Cos, Brotons and Hobbs discuss how this can improve management and outcomes of these patients.

Variability of lipid levels is predictive of CV events

Apr. 12, 2018 - Waters DD, et al. - J Clin Lipidol 2018

Visit-to-visit variability in fasting measurements of HDL-c, TG, and LDL-c is predictive of coronary events, CV events, and TG and LDL-c variability is also predictive of incident diabetes.

Slides | Type 2 diabetes & cardiovascular disease update

Mar. 15, 2018 - Barcelona, Spain - Dr. Xavier Cos - Barcelona, Spain
**EPCCS 2018** Slides prepared and presented by Dr. Xavier Cos (Barcelona, Spain), here offered as an educational service.

EPCCS 2018 Slides prepared and presented by Dr. Xavier Cos (Barcelona, Spain), here offered as an educational service.

Diabetes and vascular disease: epidemiology and management options

Dr. Xavier Cos - Barcelona, Spain

EPCCS 2018 An impression of the presentation of dr. Xavier Cos on diabetes and vascular disease, epidemiology and management options, given during the Annual EPCCS CV Summit.

Complication risk in diabetes can be predicted with new stratification

Mar. 7, 2018 - Ahlqvist E et al. - Lancet Diab Endocrinol 2018

In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.

Children with a higher BMI have an increased risk of cardio-metabolic disease later in life

Mar. 1, 2018 - Geng T, et al. - Diabetes Care 2018

A genetic predisposition to higher childhood BMI was associated with an increased risk of type 2 diabetes, coronary artery disease, and cardio-metabolic traits in adult life.

Stimulating health behaviour changes to reduce cardiovascular risk in primary care

Scroll down to download a free copy

EPCCS Consensus Guidance for Primary Care
EPCCS Consensus Guidance for Primary Care

Lifestyle importantly contributes to preventable morbidity and mortality. This EPCCS guidance document outlines the presented evidence on ingredients of successful behaviour change strategies and motivational interviewing, as well as which CV risk behaviours and clinical outcomes may be improved with various types of strategies.